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In Brief
Human hematopoietic stem cells (HSCs)
display substantial transcriptional
diversity during development. Here, we
investigated the contribution of
alternative splicing to such diversity by
analyzing the dynamics of a key
hematopoietic regulator, HMGA2. Next,
we showed that CLK3, by regulating the
splicing pattern of HMGA2, reinforces an
HSC-specific program.
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While gene expression dynamics have been exten-
sively cataloged during hematopoietic differentia-
tion in the adult, less is known about transcriptome
diversity of human hematopoietic stem cells (HSCs)
during development. To characterize transcrip-
tional and post-transcriptional changes in HSCs
during development, we leveraged high-throughput
genomic approaches to profile miRNAs, lincRNAs,
and mRNAs. Our findings indicate that HSCs
manifest distinct alternative splicing patterns in
key hematopoietic regulators. Detailed analysis of
the splicing dynamics and function of one such
regulator, HMGA2, identified an alternative isoform
that escapes miRNA-mediated targeting. We
further identified the splicing kinase CLK3 that, by
regulating HMGA2 splicing, preserves HMGA2
function in the setting of an increase in let-7 miRNA
levels, delineating how CLK3 and HMGA2 form a
functional axis that influences HSC properties
during development. Collectively, our study high-lights molecular mechanisms by which alterna-
tive splicing and miRNA-mediated post-transcri-
ptional regulation impact the molecular identity
and stage-specific developmental features of hu-
man HSCs.
INTRODUCTION
Hematopoiesis is the coordinated lineage commitment, differen-
tiation, and expansion of hematopoietic stem cells (HSCs) to
generate mature blood cells. Interestingly, hematopoiesis oc-
curs at distinct anatomic sites during development, including
the yolk sac and fetal liver during fetal life and bone marrow dur-
ing post-natal life (Mikkola and Orkin, 2006). While HSCs from
these sites are all capable of generating the full complement of
mature blood cells, they differ in certain characteristics. For
example, several studies have shown that HSCs from earlier
developmental zones have higher regenerative capacity (Ba-
bovic and Eaves, 2014). Understanding differences in hemato-
poiesis along development can shed insight on processes
important in HSC function and regeneration, with important clin-
ical applications in stem cell transplantation.Cell Stem Cell 22, 575–588, April 5, 2018 ª 2018 Elsevier Inc. 575
Recent research has leveraged high-throughput genomic
profiling to characterize the hematopoietic hierarchy at a molec-
ular level (Vedi et al., 2016). Although these studies have gener-
ated novel insights into hematopoietic lineage commitment and
differentiation, our understanding of themolecular and functional
differences among developmentally distinct HSC populations
remains inadequate. Murine studies have begun to address
this gap (Cabezas-Wallscheid et al., 2014; McKinney-Freeman
et al., 2012), but, owing to species-specific differences (Doulatov
et al., 2012), emerging efforts are starting to characterize themo-
lecular diversity along the human hematopoietic hierarchy (Notta
et al., 2016; Novershtern et al., 2011).
The generation and tuning of expression of alternative splicing
isoforms can contribute to significant transcriptional diversity
(Wang et al., 2008). However, studies are just beginning to delin-
eate their involvement in hematopoiesis (Chen et al., 2014;
Rentas et al., 2016). The discovery that core spliceosomal pro-
teins and accessory regulatory splicing factors are frequently
mutated in various hematopoietic malignancies (Sperling et al.,
2017; Yoshida et al., 2011) has further spurred research into
the regulation and role of alternative splicing during normal
hematopoiesis (Chen et al., 2014; Crews et al., 2016; Wong
et al., 2013).
Here, we dissect the transcriptional identity of human HSCs
from multiple developmental stages and establish develop-
mental stage-specific expression signatures. Through integra-
tive analyses, we then describe how alternative splicing and
microRNA (miRNA)-mediated post-transcriptional regulation
interplay to regulate HSC identity.
RESULTS
Transcriptional Diversity in Human HSCs across
Ontogeny
Fetal liver (FL), umbilical cord blood (CB), and bone marrow
(BM) represent distinct progressive stages of hematopoiesis
during development. To dissect transcriptional features of
human HSC populations, we prospectively isolated immuno-
phenotypically defined early HSCs (CD34+ CD38– CD90+
CD45RA–) from FL, CB, and BM, as well as corresponding
committed CD34+CD38+ progenitor populations (PROG). We
performed RNA sequencing (RNA-seq) and miRNA profiling
(Figure 1A).
Transitions from FL to CB and from CB to BM HSCs were
marked by substantial changes in gene expression (2,469 and
1,572 genes, respectively; false discovery rate [FDR] < 0.01) (Fig-
ure 1B, left). While recent studies have highlighted several hall-
mark genes for HSC identity (e.g., HOXA9, LMO2, MECOM;
(Ebina and Rossi, 2015), our results suggest that they are in
fact highly dynamic across HSC populations, with a limited set
of genes uniformly expressed across HSC populations (e.g.,
HLF, PRDM16—Figure S1A and Table S1). Additionally, our
analysis highlights several factors not intrinsic to HSCs, such
as genes from the niche in which HSCs develop (e.g., liver genes
like KDR and FCN2 in FL-HSCs) and genes involved in blood
pressure regulation (e.g., AVP in CB-HSCs, Figure S1B).
RNA-processing events generate splicing isoforms that vary
across cell types, contribute extensively to functional diversity
(Wang et al., 2008), and have been implicated in hematopoietic576 Cell Stem Cell 22, 575–588, April 5, 2018aging and leukemia pathogenesis (Crews et al., 2016). Thus,
we expanded our analysis to examine the transcriptional land-
scape at the isoform level (Trapnell et al., 2012). We detected
a large number of genes (215 in CB versus FL, 105 in CB
versus BM; FDR < 0.01), including key regulators HMGA2,
DNMT1, and MEIS1, that were differentially expressed among
HSC populations at the isoform level but displayed little to no dif-
ferential expression at the gene level (Figure 1B, right, and Table
S1). We also refined the isoform-level analysis by examining dif-
ferential usage of 50 UTRs, 30 UTRs, coding sequences (CDS),
and transcriptional start sites (TSS) (Figure S1C, related to
Figure 1B).
Based on the observed transcriptional diversity, we generated
a map of stage-specific mRNAs and lincRNAs, isoforms, and
miRNAs (Figure 1C and Tables S2A and S2B). As an illustration,
we highlight PROM1, previously implicated in stem cell biology
(Miraglia et al., 1997). We detected six isoforms of PROM1,
which display distinct expression patterns across HSCs. In
particular, we detected isoforms with differential inclusion of
exon 3, which encodes for part of the core prominin domain (Fig-
ures 1D and S1D).
To further understand the alternative splicing patterns in HSC
populations, we performed pairwise percent spliced-in (PSI) an-
alyses of exons among the HSC populations (Alamancos et al.,
2015). We examined different splicing events, including alterna-
tive 50 splice site (A5), alternative 30 splice site (A3), alternative
first exon (AF), alternative last exon (AL), mutually exclusive
exon (MX), retained intron (RI), and skipping exon (SE) (Figure 1E).
Interestingly, there appeared to be an increase in RI events along
HSC development from FL to CB and to BM-HSCs (both
p < 0.05).
Given the important roles for lincRNAs in stem cells (Fatica and
Bozzoni, 2014), we performed de novo lincRNA discovery from
the RNA-seq data. We identified 6905 lincRNAs, 76 of which
were differentially expressed among HSC and PROG popula-
tions, suggesting that lincRNAs contribute to transcriptional
diversity of HSCs (Figure 1C, middle, and Table S2A). MEG3,
an HSC-specific lincRNA implicated in maintenance of LT-HSC
function (Qian et al., 2016), displayed a developmentally regu-
lated expression pattern (Figure 1F).
Analysis of miRNA expression uncovered additional transcrip-
tome diversity (Figure 1C, bottom, and Table S2B). For example,
let-7 family members and miR-126 are highly expressed across
HSCs (together accounting for as much as 20% of the total
measured miRNA content) but demonstrate a developmentally
regulated expression pattern (Figure 1G).
To understand the function of the differentially expressed
genes, we applied gene set enrichment analysis (GSEA) to
examine enrichment among curated gene sets (Figure 1H). FL-
HSCs were enriched for ‘‘cell-cycle’’ and ‘‘checkpoints’’ signa-
tures. In contrast, CB-HSCswere enriched in ‘‘RNAmetabolism’’
and ‘‘30-UTR-mediated translational regulation’’ pathways.
Broad expression of target genes of known transcriptional regu-
lators (‘‘MYC targets,’’ ‘‘EZH2 targets’’) were also observed
among different HSC populations.
Together, these analyses defined developmental-stage spe-
cific molecular signatures for each HSC population that reflect
substantial transcriptional diversity at the gene and isoform
levels and which is also present in noncoding RNAs.
Figure 1. Transcriptional Diversity among Human HSCs along Development
(A) Schematic representation of fluorescence-activated cell sorting (FACS) and transcriptomic analyses. Hematopoietic stem cells (HSC) and progenitor (PROG)
cells were isolated according to the indicated surface markers from human fetal liver (FL), umbilical cord blood (CB), and bone marrow (BM) CD34+ cells. RNA
sequencing of both coding (mRNAs) and noncoding RNAs (lincRNAs) was performed along with miRNA expression quantification.
(B) (left) Pairwise comparisons showing the number of differentially expressed (DE) genes at FDR < 0.01. (right) DE transcripts at isoform level (FDR < 0.01), but not
at gene level (FDR > 0.01). Representative genes for each category are shown on the right. The full dataset can be found in Table S1.
(C) Expression heatmap of DEmRNA isoforms (top), lincRNAs (middle), and miRNAs (bottom). Representative isoforms shared among all HSC types (all-HSC) or
progenitors (all-PROG), or specific to each population (as listed on left) are indicated on the right. The full dataset can be found in Table S2.
(D) (top) Gene structure of themost highly expressedPROM1 isoforms (ISO) detected by RNA-seq. (bottom) Bar plot showingPROM1 expression (in FPKM) in the
indicated HSC samples. Reference exon numbers are listed on top (constitutive exons are not shown), with coding exons in black and UTRs in gray.
(E) Violin plot representing distributions of statistically significantDPSI values (p < 0.05) for different classes of PSI events: alternative 30 splice site (A3), alternative
50 splice site (A5), alternative first exon (AF), alternative last exon (AL), mutually exclusive exon (MX), retained intron (RI), and skipping exon (SE). Separate violins
are shown for each pairwise comparison of HSC samples, and the number of events in each violin are shown on the right. DPSI values are shown for the second
sample as compared to the first sample in each pair.
(F) MEG3 lincRNA expression quantification by RNA-seq (in FPKM) in HSC and PROG samples.
(G) Bar plot showing expression of let-7 family members (purple) and miR-126 (blue) in HSCs. Expression is shown as the percentage of total measured miRNA
counts for each HSC population.
(H) BubbleMap visualization (Spinelli et al., 2015) of representative gene set enrichment analysis (GSEA) results between pairs of HSC samples. As indicated in the
legend, for each GO category, colors (red versus blue) correspond to the sample label, shades represent statistical significance (FDR), and the area of the circle
represents the enrichment (normalized enrichment score, NES). Empty circles correspond to non-significant enrichments (FDR > 0.05). The full dataset can be
found in Table S4.
Mean ± SD values are shown for (D), (F), and (G). FPKM, fragments per kilobase of transcript per million mapped reads.
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Figure 2. HMGA2 Alternative Splicing in Human HSCs
(A) Heatmap showing expression of LIN28B, let-7 family members, the ranked median expression of the top 100 predicted let-7 targets, and HMGA2. Previously
dissected regulatory relationships of the LIN28-let-7-HMGA2 pathway (Viswanathan et al., 2008) are indicated with arrows. Scales are shown on the right as
normalized Z scores.
(B) Visualization of RNA-seq reads (black bars) mapping atHMGA2 (drawn to scale) in the indicated samples. A sashimi plot displaying the major splice junctions
(FL-HSCs, red; CB-HSCs, blue) is superimposed. The abundance of each splicing junction is indicated and is normalized to the counts for the shared exon 2–3
splice junction (with value of 1). Arrows indicate the reads mapping to the terminal exons that distinguish the HMGA2-L and HMGA2-S isoforms.
(C) Structure of the human HMGA2 locus (not drawn to scale). In the middle, locus coordinates are indicated along with coding exons (black) and UTRs (gray).
Asterisk indicates location of major chromosomal rearrangements detected in malignancies (Kazmierczak et al., 1996). Red and blue dashed lines indicate how
exons are spliced to result in HMGA2-L (top) and HMGA2-S (bottom). Gray boxes indicate the AT-binding hook domains. Green and black slashes indicate
predicted binding sites of let-7 family members and other conserved HSC-expressed miRNAs, respectively.
(D) (Top) Digital gel from RT-PCR electropherogram showing expression ofHMGA2-L andHMGA2-S from the indicated HSC populations. Sizes of the amplicons
are indicated on the right, along with the structure of each isoform (coding exons in black, UTRs in gray) and the position of the primers used for PCR co-
amplification (black dots). (Bottom) Digital gel from RT-PCR electropherogram showing expression of HMGA2 pre-mRNA from the indicated HSC populations.
HPRT1 was used as the control for both gels. Expression levels of HMGA2 isoforms are indicated in Figure S2 and Table S2A.
(E) Shaded circles show HMGA2 isoform expression (Z-score-normalized FPKM values) across HSCs and CB hierarchy from publicly available data (Stun-
nenberg et al., 2016). MPP, multipotent progenitors; CMP, common myeloid progenitors; MEP, myeloid erythroid progenitors; GMP, granulocyte macrophage
progenitors; CLP, common lymphoid progenitors.Identification of an HSC Stage-Specific HMGA2 Isoform
Our analyses identified a number of transcripts differentially ex-
pressed at the isoform level but not at the gene level (Figure 1B,
and Table S1). These include key HSC regulators whose differ-
ential expression patterns were previously undetected with
gene-level analyses. Among the most differentially expressed
was an isoform of HMGA2 (ENST00000403681.2) in the transi-
tion from FL- to CB-HSCs (>5-fold decrease, FDR < 0.01),
but which remained relatively unchanged at the gene level
(FDR >0.9) (Table S1). HMGA2 is a component of the LIN28-
let-7 axis that regulates development (Shyh-Chang and Daley,
2013). Consistent with LIN28’s role in inhibiting let-7 biogenesis
(Viswanathan et al., 2008), we observed a gradual decrease
of LIN28B during maturation from FL- to BM-HSCs, with a
concomitant increase in levels of let-7 family members (Fig-
ure 2A). Hematopoietic progenitor cells (HPCs) derived from
in vitro differentiation of induced pluripotent stem cells (iPSC)
displayed the highest levels of LIN28B and lowest levels of
let-7 members, reflecting their embryonic nature (Chadwick
et al., 2003). More broadly, we observed that the expression
of the top 100 in silico-predicted let-7 targets (Agarwal
et al., 2015) were inversely correlated with expression of let-7
(Figure 2A).578 Cell Stem Cell 22, 575–588, April 5, 2018HMGA2, a well-characterized target of let-7 (Lee and Dutta,
2007), was surprisingly discordant in expression with respect to
let-7. HMGA2 was highly expressed in both CB- and FL-HSCs,
despite let-7 levels being higher in CB as compared to FL-
HSCs (Figure 2A). RNA-seq results highlighted a complex
splicing pattern with at least four HMGA2 isoforms expressed
in HSCs (Figures S2A and S2B). Quantitative visualization of the
RNA-seq reads revealed that the canonical full-length isoform
(ENST00000403681.2; hereafter named HMGA2-L) is highly
expressed in FL-HSCs, while CB-HSCs show high expression
of a shorter isoform (ENST00000393578.3; hereafter named
HMGA2-S) (Figure 2B). HMGA2-L and HMGA2-S share the first
three exons but differ in their terminal exon usage (including
C-terminal domains and 30 UTRs) (Figures 2C and S2A). Notably,
theHMGA2-S 30 UTR is only one-third the length of theHMGA2-L
30 UTR and is devoid of most of the conserved miRNA sites,
including the seven experimentally validated let-7 sites (Mayr
et al., 2007) (Figure 2C). Semiquantitative PCR confirmed the
expression patterns of HMGA2-L and HMGA2-S isoforms (Fig-
ure 2D, top). Moreover, HMGA2 pre-mRNA levels were high
and comparable in FL- and CB-HSCs, before decreasing in
BM-HSCs, suggesting that in the transition between CB- to
BM-HSCs, HMGA2 expression is likely downregulated at the
transcriptional rather than post-transcriptional level (Figure 2D,
bottom). Global analyses identified several other genes that in
the HSC developmental transitions display a different major iso-
formwith a distinct 30 UTRdevoid of let-7binding sites (Table S3).
Using public data from the Blueprint Epigenome Project (Stun-
nenberg et al., 2016), we investigated expression of HMGA2-L
and HMGA2-S in six stem and progenitor cell populations
derived from the CB hierarchy (Figure 2E, bottom). HMGA2-S
is detectable at high levels in HSCs and in multipotent progeni-
tors. Conversely, HMGA2-L is expressed at low levels across
these same six CB-derived hematopoietic populations, consis-
tent with our data (Figure 2E, top).
Genome-wide Mapping of HMGA2 Isoform Chromatin
Binding
HMGA2 is an architectural transcription factor, binding chro-
matin broadly to help recruit other transcription factors and
regulate gene expression (Ozturk et al., 2014). To determine
whether the proteins encoded by the HMGA2 isoforms have
different functions, we evaluated HMGA2 chromatin occupancy
genome-wide by performing isoform-specific chromatin immu-
noprecipitation sequencing (ChIP-seq) in two hematopoietic
cell types: K562 cells and conditionally immortalized iPSC-
derived hematopoietic progenitors (HPC-5F) (Doulatov et al.,
2013). These cells were selected for their variable expression
of endogenous HMGA2 (Fragments Per Kilobase Million reads
[FPKM] = 0 in K562; FPKM = 44 in HPC-5F) (Uhle´n et al., 2015).
We used lentiviral constructs containing V5-tagged HMGA2-L
(L-V5) and HMGA2-S (S-V5) open reading frame (ORF) to infect
K562 and HPC-5F cells. Both V5 (Figure 3A) and HMGA2 (data
not shown) antibodies immunoprecipitated a large amount of
DNA upon overexpression (O/E) of either construct. ChIP-seq
of the immunoprecipitate from HPC-5F revealed that, unlike
the H3K4me2 profile, HMGA2 binding is broad, as recently
shown (Colombo et al., 2017), and that HMGA2-L and
HMGA2-S proteins display comparable binding patterns (Fig-
ure 3B). Ontology analysis revealed that loci with high HMGA2-L
and HMGA2-S binding are enriched for genes related to cell
cycle, DNA, and RNA metabolism (Figure S3A).
Although HMGA2 binds broadly across the genome, we iden-
tified promoter regions with the highest and the lowest level of
HMGA2 binding (see STAR Methods). We observed that pro-
moters with the highest HMGA2-L or HMGA2-S binding were
also marked by high H3K4me2 levels (V5 Hi - K4 Hi - Figure 3C).
We also observed that highly expressed genes are skewed to-
ward higher HMGA2 binding at their promoters (Figure S3B).
Additionally, within promoters that were enriched for HMGA2
binding (V5 Hi), we observed an A/T bias (Figure 3D), consistent
with in vitro observations (Winter et al., 2011). Overall, a strong
correlation of binding patterns was observed for HMGA2-L and
HMGA2-S for the most enriched and depleted promoter regions
(r2 = 0.99 Figure 3E).
HMGA2 Promotes Expression of HSC-Specific Genes
and Enhances Engraftment Capacity
To examine the effects of the two isoforms on downstream gene
expression, we performed RNA-seq from HPC-5F transduced
with either HMGA2-L or HMGA2-S ORFs, or control vector
(CTRL). A high correlation in downstream gene expressionwas observed between HMGA2-L and HMGA2-S treatments
(r2 = 0.95, Figures 3F and S3C). HPC-5F cells have been previ-
ously shown topartially reactivate anHSCsignatureand toenable
short-term engraftment into immunocompromised mice (Doula-
tov et al., 2013). GSEA revealed that enforced expressionof either
HMGA2-L or HMGA2-S ORFs enhanced expression of a broad
HSC-specific gene signature (Figure 3G). No significant differ-
ences were detected when comparing HMGA2-L to HMGA2-S
treatment. Moreover, we observed enhanced repopulating ca-
pacity of HPC-5F cells uponO/E of eitherHMGA2-L orHMGA2-S
ORFs in immunocompromised mice at 16 weeks (Figure 3H).
Collectively, these results revealed that HMGA2-L and
HMGA2-S proteins, despite differences in their C-terminal do-
mains, are highly comparable in their chromatin binding patterns
and ability to induce transcriptional changes. The results also link
HMGA2 function to activation of an HSC-specific program and
enhanced self-renewal.
miRNA-Mediated Post-transcriptional Regulation
Dictates Differential HMGA2 Isoform Stability
Since HMGA2-L and HMGA2-S utilize different 30 UTRs (Fig-
ure 2C), we hypothesized that the distinct expression patterns
(Figure 2D) of the isoforms between FL- and CB-HSCs
could be functional in preventing miRNA-mediated post-tran-
scriptional regulation. To test this, we generated reporter
constructs with luciferase fused to either the wild-type
HMGA2-L 30 UTR (Rluc-30UTRwt_HMGA2-L), HMGA2-S 30
UTR (Rluc-30UTRwt_HMGA2-S), or to a HMGA2-L 30
UTR mutated at all HSC-expressed miRNA binding sites (Rluc-
30UTRmt_HMGA2-L).
We transfected the luciferase reporter constructs into Dgcr8-
knockout mouse embryonic fibroblasts (MEFs K/O DGCR8),
along with seven individual HSC-expressed miRNAs and a
scramble control. Knockout of Dgcr8 prevents endogenous
miRNA processing, which isolates the role of each miRNA in
the absence of endogenous miRNA activity (Han et al., 2009).
Among the seven miRNAs analyzed, we found that let-7 family
members had the strongest repressive effect on luciferase activ-
ity of HMGA2-L 30 UTR (Figure 4A, left). This effect was reversed
upon mutation of binding sites for those miRNAs. Additionally,
other HSC-expressed miRNAs also appeared to regulate
HMGA2-L (Figure 4A, left). Moreover, the activity of the construct
containing HMGA2-S 30 UTR was higher than that of HMGA2-L
30 UTR in the context of most miRNA treatments (Figure 4A,
right), indicating that HMGA2-S 30 UTR has a higher capacity
to escape miRNA-mediated repression.
Having demonstrated that the HMGA2-L 30 UTR is regulated
by a number of miRNAs, we next evaluated whether miRNA-tar-
geting might drive differential stability of the two HMGA2 iso-
forms. We used PC-3 and HPC-5F cells, which display high
and low endogenous levels of the identified miRNAs, respec-
tively (Figure 4B). Constructs carrying HMGA2-L and HMGA2-S
ORFs along with their corresponding 30 UTRswere used to infect
cells, which were then treated with actinomycin-D for 6 hr to halt
transcription allowing us to isolate the effect of mRNA stability.
qPCR of theHMGA2 isoforms revealed thatHMGA2-L+30UTRwt
was more rapidly destabilized than HMGA2-S+30UTRwt
(Figure 4C). Conversely, HMGA2-L+30UTRmt expression re-
mained stable over the time points. Overall, we observed thatCell Stem Cell 22, 575–588, April 5, 2018 579
Figure 3. Protein Function of HMGA2 Isoforms
(A) Amount of DNA immunoprecipitated using V5 antibody in K562 and HPC-5F cells transduced with a control (C) or V5-tagged HMGA2-L (L) or HMGA2-S (S)
ORF lentiviral overexpression (O/E) constructs. Mean ± SEM values are shown.
(B) Visualization of ChIP-seq read mapping at a sample locus. HPC-5F cells were transduced with V5-tagged HMGA2-L or HMGA2-S ORF constructs for
overexpression of the protein coding regions of the respective isoforms (L or S). ChIP-seq profiles are shown for tagged-HMGA2 (V5) or H3K4me2 (K4me2).
Genes at the locus are indicated on the bottom.
(C) Number of gene promoters (total n = 28,314) enriched for HMGA2 (V5) and H3K4me2 (K4) upon overexpression of HMGA2-L (HMGA2-L-V5) or HMGA2-S
(HMGA2-S-V5) ORFs. Promoters are considered highly enriched (Hi) for V5 or K4 if they rank in the top quartile of normalized read counts or depleted (Lo) if they
fall in the bottom quartile.
(D) A/T content (as a percentage) within immunoprecipitated promoter regions in the V5 Hi and V5 Lo categories or total promoter regions (as a background
control). First and third quartiles, medians, and interquartile ranges are shown.
(E) HMGA2-L and HMGA2-S binding enrichment analysis shows 8456 differentially enriched promoters over the background signal. Correlation between
HMGA2-L (L) and HMGA2-S (S)-enriched promoters is shown for V5 Hi and V5 Lo fractions. Values are reported as the log2 sum of ChIP replicate signals at
promoter regions. PCC is Pearson’s correlation coefficient (r2). Enrichment of GO categories from V5 Hi promoters are shown in Figure S3A.
(F) Differential expression analysis identified 1,078 differentially expressed genes between HMGA2-L and HMGA2-S and control. Correlation in expression
between HMGA2-L (L) and HMGA2-S (S) treatments is shown. Values are reported as log2 average of FPKM replicates. PCC is Pearson’s correlation coefficient
(r2). The full pairwise comparisons are shown in Figure S3C.
(G) BubbleMap visualization (Spinelli et al., 2015) of GSEA results in HPC-5F cells transduced with HMGA2-L and HMGA2-S ORFs or control (CTRL) vectors.
Gene sets were derived from HSC and PROG-specific signatures from Figure 1C (see Table S2C). As indicated in the legend, colors (red versus blue) correspond
to the sample label, shades represent statistical significance (FDR), and the area of the circle represents the enrichment (normalized enrichment score, NES).
Empty circles correspond to non-significant (NS) enrichments (FDR > 0.05).
(H) Human chimerism as percentage of GFP+CD45.1+ in the injected femur of xenografted mice 16 weeks after transplantation of HPC-5F cells transduced with
lentivirus for HMGA2-L ORF, HMGA2-S ORF, or CTRL. Individual and mean values are shown. Mann-Whitney test was used individually comparing each
indicated sample with respect to CTRL; *p < 0.05.
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Figure 4. Post-transcriptional Regulation of HMGA2 Isoforms
(A) Left: Normalized luciferase (Renilla) activity in Dgcr8-KO MEF of constructs carrying 30 UTR sequences of HMGA2-L (Rluc-30UTRwt_HMGA2-L) or a mutant
derivative depleted for miRNA sites (Rluc-30UTRmt_HMGA2-L). Right: Normalized luciferase (Renilla) activity in Dgcr8-KO MEF of constructs carrying 30 UTR
sequences of HMGA2-L (Rluc-30UTRwt_HMGA2-L) or HMGA2-S (Rluc-30UTRwt_HMGA2-S). Normalized luciferase activities were reported with respect to
Rluc-30UTRmt_HMGA2-L (left) or Rluc-30UTRwt_HMGA2-S (right), set to 100%. Mean ± SEM values are shown. Unpaired t test was used; *p < 0.05, **p < 0.01,
***p < 0.005, borderline (० = 0.055).
(B) Quantification of miRNAs of interest in PC-3 and HPC-5F cells measured by qRT-PCR. U6 small nuclear RNA (snRNA) was used as control.
(C) Relative quantification of HMGA2 isoforms in PC-3 and HPC-5F cells transduced with lentiviral constructs carrying the HMGA2 ORFs equipped with their
corresponding 30 UTRs (HMGA2-L+30UTRwt and HMGA2-S+30UTRwt) or a derivative HMGA2-L isoform mutated at its miRNA sites (HMGA2-L+30UTRmt).
Infected cells were treated with actinomycin D (Act-D) and harvested at the indicated time points. Expression values were normalized to HPRT1 control and then
reported with respect to HMGA2-S+30UTRwt, set to 1. Mean ± SEM values are shown. ANOVA was used; *p < 0.05, **p < 0.01, ***p < 0.005.HMGA2-L+30UTRwt destabilization was more pronounced in
cells with higher expression of the miRNAs of interest (Figures
4B and 4C).
To demonstrate the regulation of HMGA2-L in endogenous
settings, we utilized miRNA inhibitors against miRNAs highly
expressed in CB-HSCs (let-7 and miR-142, Figure 5B). Consis-
tent with reporter assay results above, inhibition of let-7 and
miR-142 in CB CD34+ cells increased expression of HMGA2-L
(Figure S4A).
Taken together, these data demonstrate that HMGA2-L
and HMGA2-S isoforms are differentially regulated at the
post-transcriptional level and that miRNA levels are critical in
determining their stability. These results reconcile the discor-
dant let-7 and HMGA2 expression patterns seen in the HSC
RNA-seq (Figure 2A). In FL-HSCs, where HMGA2-L is the
primary isoform (Figure 5A), the cumulative levels of let-7
and other miRNAs shown to target HMGA2-L are the lowest
among the HSC populations (Figure 5B). In contrast, in CB-
HSCs, where HMGA2-S represents the primary isoform (Fig-
ure 5A), the expression of these miRNAs was much higher,
representing more than 40% of the total measured miRNA con-
tent (Figure 5B).
Modulation of HMGA2 Isoforms Influences Human HSC
Function In Vitro
To determine whether HMGA2 isoform dynamics impact HSC
properties, we tested their role on human HSC function in vitro.
We first depleted HMGA2 using isoform-specific small hairpin
RNA (shRNA)-mediated knockdown (KD) in CB CD34+ cells (Fig-
ure 5C). We designed shRNAs that target only the long
(shLONG), short (shSHORT), or both isoforms (shBOTH) (Fig-
ure S4B). After 1 week of cytokine-driven serum-free culture,
KD of either HMGA2 isoform in CB CD34+ decreased total cell
output (data not shown), as well as the CD34+CD133+CD38–HSC-enriched population (Figure 5D). We also found a reduction
in colony-forming potential upon KD of either HMGA2-S and
HMGA2-L (Figure 5E, left). Next, we performed a rescue exper-
iment by co-infecting CB CD34+ cells with shBOTH as well as
constructs expressing either the HMGA2-L and HMGA2-S
ORFs that bear optimized sequences to escape targeting by
shBOTH (see STAR Methods). HMGA2 ORFs restored colony
output of shBOTH-treated CB CD34+ cells (Figure 5E, right).
Interestingly, we also observed a significant increase of E and
GEMM colonies upon HMGA2 O/E, consistent with the role of
HMGA2 as a positive regulator of erythropoiesis (Copley et al.,
2013; Ikeda et al., 2011).
We next evaluated the effect of O/E of each isoform
when under the control of its corresponding 30 UTR (Figure 5C).
We performed this experiment in primary BMCD34+ cells, which
have low total HMGA2 expression (Figure 5A). Cytokine-driven
serum-free culture of transduced BM CD34+ cells revealed a
significant increase in CD34+CD133+CD38– HSC numbers
upon O/E of HMGA2-L+30UTRmt and HMGA2-S+30UTRwt
after 1 week of culture (Figure 5F). Forced expression of
HMGA2-L+30UTRmt or HMGA2-S+30UTRwt also increased the
colony forming potential of transduced BMcells when compared
to CTRL. The observed phenotype was more pronounced in
HMGA2-S+30UTRwt as compared to HMGA2-L+30UTRmt, with
no differences observed in HMGA2-L+30UTRwt-transduced
cells (Figure 5G). These results support the functional role of
HMGA2-S in regulating HSC self-renewal and clonogenic poten-
tial capacity in vitro.
CLK3 Regulates HMGA2 Splicing Pattern
through SRSF1
We next interrogated the mechanism by which HSCs are able to
tune expression of the HMGA2 isoforms. To do so, we tested
splicing regulators for their effect onHMGA2 isoform expression.Cell Stem Cell 22, 575–588, April 5, 2018 581
Figure 5. Modulation of HMGA2 Isoforms in Human HSPCs
(A and B) Absolute expression of the indicated HMGA2 isoforms (in FPKM) (A) and miRNA families (as percentage of total measured miRNA content) (B) in the
indicated HSC populations.
(C) Scheme of HMGA2 isoform modulation experiments in CB and BM CD34+ hematopoietic stem and progenitor cells (HSPCs). Lentiviral constructs (pLKO.1
and pLENTI) also express GFP as a marker to allow for isolation of infected cells.
(D) Phenotypic analysis of the stem cell compartment (CD133+CD34+CD38–) in CB CD34+ cells transduced with negative-control hairpin (luciferase-shLUC) or
HMGA2 isoform-specific shRNAs (shHMGA2-S or shHMGA2-L) following 7 days in culture.
(E) Left: Clonogenic progenitor assay of CD34+ CB cells following KD of HMGA2 isoforms. Cells transduced with shLUC, shHMGA2-S, and shHMGA2-L hairpins
were plated 3 days post-infection andCFUpotential wasmeasured 14 days post-plating. (right) CFU potential of CD34+CB transducedwith hairpins against both
HMGA2 isoforms (shBOTH) was rescued upon overexpression of either the HMGA2-L or HMGA2-S ORFs.
(F) Phenotypic analysis of the stem cell compartment (CD133+CD34+CD38–) in BM CD34+ cells transduced with CTRL, HMGA2-L+30UTRwt, HMGA2-L-
+30UTRmt, or HMGA2-S+30UTRwt constructs after 7 days in culture.
(G) Clonogenic progenitor assay of CD34+ BM cells following overexpression of HMGA2 isoforms. Cells transduced with CTRL were plated 3 days after infection
and CFU potential was measured 14 days post-plating.
Mean ± SEMvalues are shown for (D)–(G). Analysis of deviance for generalized linearmodels (CFU analyses) or repeated-measures ANOVA (FACS analyses) were
used; *p < 0.05 or **p < 0.01, non-significant (NS).We first filtered known splicing regulators to 23 candidates
(Figure 6A) and then overexpressed each of these factors in
PC-3 cells, which endogenously express bothHMGA2 isoforms.
Among factors tested,CLK3 had the strongest effect onHMGA2
isoform switching (Figure 6B). CLK3 belongs to the CDC-like
kinases (CLK1–4) family of dual-specificity protein kinases,
which regulate alternative splicing through phosphorylation of
serine/arginine-rich domains on direct splicing factors (Colwill
et al., 1996). To provide further evidence, we treated PC-3 cells
with shRNAs against CLK3 (shCLK3) and observed a decrease
of HMGA2-S with a corresponding increase of HMGA2-L
expression (Figure S5A). Among HSCs profiled, CLK3 expres-582 Cell Stem Cell 22, 575–588, April 5, 2018sion was the highest in CB HSCs (Figure 6C) and correlated
withHMGA2-S expression across the CB hierarchy (Figure S5B).
To investigate whetherCLK3 affects theHMGA2 splicing pattern
in human HSCs, we transduced BM CD34+ with lentiviral con-
structs overexpressing CLK3 or a CTRL (Figure 6D). BM
CD34+ cells were chosen for their low endogenous CLK3 and
HMGA2 levels. RNA-seq analysis 4 days after infection of
CLK3 demonstrated stimulation of expression ofHMGA2-S (Fig-
ures 6E and S5C). Interestingly, expression of an additional
isoform bearing a short 30 UTR (HMGA2-S’’) distinct from
HMGA2-S and HMGA2-L was also stimulated upon CLK3 O/E;
this HMGA2-S’’ isoform is normally expressed at very low levels
Figure 6. CLK3 Affects HMGA2 Splicing through SRSF1
(A) Schematic representation of the filtering strategy to identify regulators ofHMGA2 splicing. Genes were selected for theGO term ‘‘RNA binding’’ (GO:0003723),
minimum expression, and ratio of expression in CB-HSC versus FL-HSC, as in the scheme.
(B) Ratio of expression of HMGA2-S/HMGA2-L following overexpression of the indicated candidate splicing factors in PC-3 cells. Controls (GFP and RFP) are
shaded in gray. Values were normalized to the HMGA2-S/HMGA2-L ratio upon control GFP overexpression and shown as mean ± SEM.
(C) CLK3 expression by RNA-seq (in FPKM) in the indicated HSC populations. Mean ± SD values are shown. FDR <0.01 (**).
(D) Schematic representation of CLK3 modulation in BM HSPCs.
(E)HMGA2 isoform quantification by RNA-seq (in FPKM) in BM-HSCs isolated upon overexpression ofCLK3 or CTRL 4 days post-infection.Mean ±SD values are
shown. PCR validation is shown in Figure S5C.
(F) Violin plot representing distributions of statistically significant (p < 0.05)DPSI values for different classes of PSI events (as in Figure 1H) inCLK3 overexpression
as compared to vector control. Individual significant events are shown. The number of events of each PSI class are shown below the plot.
(G) Schematic representation of HMGA2-L genomic structure (coding exons in black, UTRs in gray). SRSF1 binding motif sites are indicated by arrows in the
corresponding exons. Sequence of exon 4 is shown, and the predicted SRSF1 site is underlined in red.
(H) Schematic representation of the luciferase-based splicing reporter constructs. The pcDNA3.1-Luc plasmid contains an intron-spaced Firefly luciferase coding
sequence (gray boxes) that produces bioactive luciferase protein only upon proper splicing of the intervening intron. The HMGA2-L genomic region encom-
passing exon 4 (black box) plus 500 bp on either side of the flanking introns (wild-type [WT] or mutated [mut] by deletion of SRSF1 site) was cloned into the
intron of pcDNA3.1-Luc. Its inclusion in the luciferase coding sequence abolishes bioactive luciferase. Normalized luciferase activities were tested with or without
CLK3 overexpression and reported with respect to Luc-exon-4 WT set to 100%. Mean ± SEM values are shown. Repeated-measures ANOVA was used;
*p < 0.05.in HSCs (Figures S2A and S2B). A similar effect of stimulating
HMGA2-S expression was also observed in HPC-5F cells upon
CLK3 O/E (Figure S5D).
To evaluate the impact of CLK3 O/E on the global repertoire
of splicing events in BM-HSCs, we performed a DPSI analysis
as above (see STAR Methods). For most types of PSI events,
approximately the same number of events were induced
byCLK3O/E as were depleted. However,CLK3O/E significantly
increased exon skipping (SE) events (Figure 6F, p = 8.263 10–30)
and promoted intron retention (RI, Figure 6F, p = 4.99 3 10–8).
These results suggest a global role ofCLK3 in mediating alterna-
tive splicing.Interestingly, exons preferentially spliced out upon CLK3 O/E
were enriched for SRSF1 binding motifs (p = 0.0016) (Park
et al., 2016). SRSF1 is known to bind exonic enhancer se-
quences (ESE) and act as a barrier to prevent exon skipping
(Long and Caceres, 2009). As SR proteins are regulated by
CLK proteins, we searched for predicted SRSF1 binding sites
in HMGA2. Motif analyses identified SRSF1 binding motifs only
in the HMGA2-L mRNA sequence, specifically in exons 4
and 5, which are exclusive to HMGA2-L (Figure 6G). To test
whether CLK30s effect on HMGA2 splicing is mediated by
SRSF1, we cloned exon 4 of HMGA2-L (including flanking
intronic regions [500 bp]) into a luciferase splicing reporterCell Stem Cell 22, 575–588, April 5, 2018 583
Figure 7. CLK3-HMGA2 Axis Orchestrates an HSC-Specific Program
(A) Phenotypic analysis of HSC content in BM CD34+ cells transduced with CTRL or CLK3 lentiviral constructs 4 days post-infection. Mean ± SEM values are
shown. Unpaired t test was used, **p < 0.01.
(B) BubbleMap visualization (Spinelli et al., 2015) of GSEA results in BM-HSCs upon CTRL, CLK3, or HMGA2-S+30UTRwt overexpression. Gene sets were
derived from HSC and PROG-specific signatures from Figure 1C (see Table S2C). As indicated in the legend, colors (red versus blue) correspond to the sample
label, shades represent statistical significance (FDR), and the area of the circle represents the enrichment (normalized enrichment score, NES). Empty circles
correspond to non-significant (NS) enrichments (FDR > 0.05). Representative GSEA plot of the boxed BubbleMap is shown on the right.
(C) Venn diagrams of genes significantly DE (FDR < 0.05) upon CLK3 or HMGA2-S+30UTRwt overexpression.
(D) RNA-seq-based expression (in FPKM) of representative genes upon CTRL, CLK3, and HMGA2-S+30UTRwt overexpression in BM HSCs. Mean ± SD values
are shown. Cufflinks FDR <0.05 in all comparisons.
(E) Human chimerism as percentage of GFP+CD45.1+ in the injected femur of xenografted mice 8 weeks after transplantation of BM CD34+ HSPCs transduced
with lentivirus for HMGA2-S+30UTRwt, CLK3, or CTRL. Individual sample, mean ± SEM values are shown. Mann-Whitney test was used to individually compare
each indicated sample with respect to CTRL, *p < 0.05.(Luc-exon-4WT) (Figure 6H, top) (Martone et al., 2016). A version
of HMGA2-L exon 4 that is mutated for the SRSF1 binding motif
was also generated. Upon CLK3 O/E, luciferase activity of the
WT construct was enhanced, indicating thatCLK3O/E promotes
skipping of the exon containing an SRSF1 binding motif. The
observed effect was further enhanced when the SRSF1 site in
that exon wasmutated (Figure 6H, low).CLK3O/E did not further
increase luciferase activity of the mutated construct, supporting
the direct molecular link between CLK3 and SRSF1. qPCR in
PC-3 cells treated with SRSF1-specific small interfering
RNAs (siRNAs) further confirm that depletion of SRSF1 affects584 Cell Stem Cell 22, 575–588, April 5, 2018HMGA2 splicing by decreasing HMGA2-L and increasing
HMGA2-S expression (Figure S5E), phenocopying the effect
of CLK3 modulation (Figures 6B and S5A). Collectively, these
results indicate that CLK3 promotes the skipping of HMGA2-L
exon in a SRSF1-dependent manner.
CLK3-HMGA2-S Axis Orchestrates an HSC-Specific
Program
Flow cytometry revealed a >4-fold increase of HSCs upon CLK3
O/E 4 days post-infection of BM CD34+ (as compared to CTRL)
(Figure 7A). A similar trend, albeit to a lesser extent, was
observed upon CLK3 O/E in CD34+ CB cells, possibly due to
higher endogenous CLK3 expression (Figure S6A). Next, we
evaluated the global effect of CLK3 O/E on the transcriptional
landscape in BM HSCs. GSEA revealed that CLK3 O/E rein-
forced a BM-HSC gene signature and reactivated a CB-HSC
gene signature (Figure 7B). Interestingly, we observed that
CLK3 O/E reactivates a broad HSC signature in HPC-5F (Fig-
ure S6B), similar to the effect observed with forced expression
of HMGA2 ORFs (Figure 3G). Furthermore, the impact of CLK3
on the HSC transcriptional landscape was phenocopied by
HMGA2-S+30UTRwt O/E in BM-HSCs (Figure 7B). On a global
level, we detected an overlap of the genes modulated upon
CLK3 and HMGA2-S treatment, with 50% of the total of genes
modulated upon CLK3 O/E displaying the same trend upon
HMGA2-S O/E (Figure 7C). This included higher expression of
key regulators of the HSC program in BM-HSCs transduced
with CLK3 and HMGA2-S+30UTRwt (Figure 7D).
To further support our observation that CLK3-mediated pro-
motion of stemness potential is mediated by HMGA2-S, we per-
formed a rescue experiment by co-infecting CBCD34+ cells with
shCLK3 and anHMGA2-SO/E construct. CFU analysis revealed
that shCLK3 treatment of CB CD34+ significantly reduced E and
GEMM colonies (Figure S6C), paralleling the effect of HMGA2-S
KD (Figure 5E), In contrast, co-overexpression of HMGA2-S
rescued the output of E and GEMM colonies (Figure S6C).
To evaluate whether elevation of HSC-specific gene expres-
sion enhances HSC function in vivo, we transduced human BM
CD34+ cells with HMGA2-S+30UTRwt, CLK3, or CTRL vectors
and transplanted cells into immunodeficient mice. Human BM
CD34+ cells display significantly reduced proliferative potential
in vivo compared to CB and FL cells, corresponding to an age-
related decline in HSC function (Bernitz et al., 2016). Consistent
with this, CTRL-treated BM cells displayed only 1% engraft-
ment at 8 weeks post-transplant. In contrast, induction of
HMGA2-S+30UTRwt or CLK3 significantly enhanced the human
chimerism (Figure 7E). Collectively, our findings demonstrate
that CLK3, at least in part by regulating the splicing pattern of
HMGA2, reinforces an HSC-specific program in vitro and in vivo.
DISCUSSION
Recent studies have leveraged high-throughput genetic, epige-
netic, and transcriptomic data to better understand the underly-
ing mechanisms of hematopoiesis (Notta et al., 2016). Here, we
have comprehensively characterized the transcriptional land-
scape of HSCs along development (FL, CB, and BM), including
gene and isoform-level expression of coding genes, as well as
expression of non-coding RNAs. Building on prior work (Chen
et al., 2014), our analyses highlighted extensive alternative
splicing among HSC populations, including a stage-specific
alternative splicing pattern for HMGA2. Comprehensive func-
tional experiments further reveal that interplay between alterna-
tive splicing andmiRNA-mediated regulation profoundly impacts
regulation and expression ofHMGA2, with consequences for the
molecular identity and behavior of human HSCs.
HMGA2 is an important downstream effector of the LIN28/let-7
pathway (Viswanathan et al., 2008), and its expression is tightly
regulated at its 30 UTR by let-7 miRNAs (Lee and Dutta, 2007).
Expression of aberrant HMGA2 transcripts is frequently seen inhuman malignancies (Schoenmakers et al., 1995) as the result of
chromosomal rearrangements, and has been observed in a single
patient in a gene therapy trial, as a consequence of insertional
mutagenesis that dissociate the HMGA2 30 UTR from its protein-
coding region (Cavazzana-Calvo et al., 2010). Loss of let-7 sites
hasbeenproposedas themajordriverofHMGA2-mediatedonco-
genic transformation (Fedele et al., 1998; Mayr et al., 2007) and
promotion of hematopoietic cell proliferation (Ikeda et al., 2011).
Here, we report that CB-HSCs express an alternativeHMGA2 iso-
form bearing a 30 UTR devoid of miRNA sites (HMGA2-S) and that
expression of HMGA2-S allows for preserved expression and
function of HMGA2 in spite of physiologically high levels of let-7
and other miRNAs present in CB-HSCs. Independent reports
have implicated HMGA2 in promoting cell proliferation and stem
cell properties in different contexts (Copley et al., 2013; Ikeda
et al., 2011; Li et al., 2007; Nishino et al., 2008). Our work expands
the roleofHMGA2 inHSCsandprovidesevidence for similar func-
tions of the proteins encoded by the two HMGA2 isoforms.
Our work also delineated the molecular mechanism for
differential HMGA2 splicing observed across HSCs. Here, we
describe the role of a splicing kinase, CLK3, in impacting HSC
development by promoting expression of an HMGA2 isoform
insensitive to miRNA-mediated targeting. Indeed, we observed
a substantial overlap between genes modulated by either
CLK3 or HMGA2-S. We also demonstrate that enforced expres-
sion of CLK3 and HMGA2-S can induce a more proliferative
phenotype in BM-HSCs by reactivating a CB-specific tran-
scriptional signature and promoting engraftment of human BM
HSPCs, which normally display low repopulating capacity.
Furthermore, we demonstrated that CLK3 stimulates exon
skipping, including at HMGA2. A dynamic cycle of phosphoryla-
tion anddephosphorylation of SRproteins is essential for splicing
(Mermoud et al., 1994). Among splicing kinases, CLK proteins
have broad roles in this phosphorylation process to regulate
SR proteins (Ngo et al., 2005, Aubol et al., 2016). In line with pre-
vious observations that high levels of CLK inhibit the activity of SR
proteins in promoting splicing (Prasad et al., 1999), we show that
(1) exons preferentially spliced out upon CLK3 O/E are enriched
for SRSF1 binding sites; (2) only HMGA2-L (and not HMGA2-S)
contains SRSF1 binding sites; and (3) CLK3 O/E affects
HMGA2-L proper splicing by preventing SRSF1 activity at its
binding sites. Thus, in the context of HMGA2, we have demon-
strated that CLK3 acts through SRSF1 to shift the balance of
HMGA2-L versus HMGA2-S splicing.
In summary, we showmarked differences among HSCpopula-
tions at different developmental stages and implicate alternative
splicing as a mechanism that contributes to the transcriptional di-
versity. Our comprehensive map of the transcriptome of HSCs
represents a valuable tool for understanding the mechanisms of
hematopoiesis that can be applied to complement and improve
cell fate conversion and HSC expansion approaches.
Our work also expands the canonical LIN28/let-7 pathway,
where LIN28 proteins inhibit let-7 biogenesis, which in turn
repress expression of target genes, including HMGA2 (Lee and
Dutta, 2007). Our results highlight a physiologic isoform of
HMGA2 that escapes regulation by the upstream LIN28/let-7
pathway. CLK3 appears to function as a tuner that, by regu-
lating the balance of HMGA2 isoforms, impacts the develop-
mental identity of HSCs. Collectively, our findings open up newCell Stem Cell 22, 575–588, April 5, 2018 585
directions of investigation into the mechanisms of altered
HMGA2 splicing that might contribute to developmental regula-
tion and malignancies.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Primary hematopoietic cell source and FACS analyses
Human CD34+ cells (Lonza and AllCells) from all sources were obtained as viable frozen states. The ages of the individuals used for
the profiling and treatments are as follows: FL-CD34+ (17-20 weeks of gestation); CB-CD34+ (newborns); BM-CD34+ (24-36 years
old). For the generation of HSC/PROG transcriptional profiles, at least three distinct lot numbers, each corresponding to independent
individuals or pools of distinct individuals (of random male or female samples), were utilized to attain maximal representation. For
each biological replicate, HSC and PROG populations were sorted from the same pool of cells. Cells were stained and sorted using
a BD FACS Aria II cell sorter for panels of cell surface markers and dyes as indicated below.
HSC panel: CD34 PE-Cy7 (8G12; BD), CD38 PE-Cy5 (HIT2; BD), CD90 PE (5E10; BD), CD45RA-FITC (HI100; BioLegend), DAPI
PROG panel: CD34 PE-Cy7 (8G12; BD), CD38 PE-Cy5 (HIT2; BD), DAPI
Stem Cell panel: CD34 PE-Cy7 (8G12; BD), CD38 PE-Cy5 (HIT2; BD), CD90 PE (5E10; BD), CD45RA-V450 (HI100; BD),
CD133/1-APC (AC133; Miltenyi Biotec)Cell Stem Cell 22, 575–588.e1–e7, April 5, 2018 e3
Cell culture and viral transduction
All cell culture incubations were performed at 37C with 5% CO2. cDNA sequences for overexpression were cloned into a pSMAL-
GFP or pSMAL-BFP (Doulatov et al., 2013) or pLVX-PURO (Clontech) lentiviral backbone, using Infusion HD Cloning Kit (Clontech).
HMGA2 cDNAs were cloned as full ORF sequences including wild-type or mutated 30UTRs (see below), as ORFs only, or as RNAi-
resistant ORFs (by degenerating the shRNA target sequences). For RNA interference, shRNA sequences were cloned in the
pLKO.1_hPGK-Puro-CMV-tGFP lentiviral backbone (Sigma-Aldrich). Lentiviral particle productions and quantifications were per-
formed using standard procedures. CB and BM CD34+ cells were thawed and plated in X-VIVO media (Lonza) supplemented with
20% BIT 9500 (StemCell Technologies), 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin, and incubated for 4-6 hours
before transduction. Cells were then seeded on retronectin-coated (10 mg/cm2) 96 well plates (Clontech) at a density of
0.5-1x105 cells per well, and viral particles were added at a multiplicity of infection (MOI) of 30-50 (for the KD treatments) or
100 (for the overexpression treatments) in a final volume of 150 ml. The following cytokines were used along with protamine sulfate
at 8 mg/ml (Sigma-Aldrich): stem cell factor (SCF) 100 ng/ml, Flt3 ligand (FLT3-L) 100 ng/ml, thrombopoietin (TPO) 50 ng/ml, and
interleukin 6 (IL-6) 20 ng/ml (all PeproTech). Cells were then spinfected for 1 hr at 2500 rpm at room temperature (RT) and sub-
sequently incubated for a minimum of 24 hr before changing media. Cells were then expanded in StemSpan SFEM (StemCell
Technologies), supplemented with half the concentration of the indicated cytokines. Infected cells were sorted 3 days post-trans-
duction for use in downstream assays. HPC and HPC-5F were obtained according to (Doulatov et al., 2013). Infection was per-
formed in StemSpan SFEM (StemCell Technologies) with 50 ng/ml SCF, 50 ng/ml FLT3, 50 ng/ml TPO, 50 ng/ml IL6, 10 ng/ml IL3
(all R&D Systems) and an MOI of 5-10 was used for the indicated constructs. Media was changed 24 hr post-infection and sup-
plemented with doxycycline at 2 mg/ml (Sigma-Aldrich) to allow for the expression of the 5 factors. Prostate cancer cells (PC-3)
and K562 cells were obtained from ATCC and cultured according to the suggested specifications. Cells were transduced with
an MOI of 4-8 and media was changed 24 hr after infection. Cell were treated with Actinomycin D at 1mg/ml (Sigma-Aldrich)
for the indicated amount of time and then harvested.
Colony forming unit assays
1x103 cells were plated into 3 ml of complete MethoCult (H4434; StemCell Technologies) and supplemented with 10 ng/ml FLT3,
10 ng/ml IL6, and 50 ng/ml TPO (all PeproTech). Colonies were scored manually after 14 days of incubation.
Mouse transplantation and assessment of human cell engraftment
NOD/LtSz-scidIL2Rgnull (NSG) (Jackson Labs)micewere bred and housed at the Boston Children’s Hospital animal care facility, and
experiments were performed in accordance to institutional guidelines approved by the BCH animal care committee. Briefly,
6-10 week old female mice were irradiated (275 rads) 24 hr before transplant. BM-transduced cells were GFP+ sorted 3 days
post-infection. 7.5x104 cells were transplanted per mouse in a 25 ml volume using a 28.5g insulin needle after temporarily sedating
the animals with isoflurane. For HPC-5F transplantation experiments, cells were cultured for 14 days before injection, and 8x106 cells
were transplanted per mouse. For all the transplantation experiments, Sulfatrim was administered in drinking water to prevent infec-
tions after irradiation. Mice were sacrificed at the indicated time points. Injected femur, uninjected femur, and tibiae were collected
and single cell suspensions were prepared using standard flushing and cell dissociation techniques. Samples were stained with a
panel of human markers: CD19 PE (4G7; BD), CD45 PE-Cy5 (Immu19.2; Coulter), CD45 APC-Cy7 (2D1; BD), CD33 APC
(P67.6; BD) and DAPI. Uninjected mouse bone marrow was used as a control for non-specific staining and BM mononuclear cells
(Lonza) were used as a positive control for antibody staining, and proper compensation. All acquisitions were performed on a BD
Fortessa cytometer.
Luciferase reporter assays
For the HMGA2-30UTR reporter assay, 30UTR sequences for the HMGA2-L (Rluc-30UTRwt_HMGA2-L) and HMGA2-S
(Rluc-30UTRwt_HMGA2-S) isoforms were cloned into psiCHECK2 plasmid (which contains both Renilla [Rluc] and Firefly [Fluc] lucif-
erases from Promega) downstream of the Renilla luciferase (Rluc) ORF. A mutant derivative of HMGA2-L 30UTR mutated for all the
miRNA binding sites of interest (Rluc-30UTRmt_HMGA2-L) was synthesized (GeneScript). Dgcr8 K/OMEFs (Novus Biologicals) were
transfected along with miRIDIAN microRNA mimics using the DharmaFECT Duo reagent (Dharmacon). Rluc and Fluc activities were
measured by Dual Luciferase assay (Promega) 72 hr after transfection. Ratios between Rluc and Fluc were calculated, and outliers of
biological triplicates removed. To report HMGA2-L 30UTR stability upon deletion of themiRNA sites, Rluc-30UTRwt_HMGA2-L values
were normalized to those of Rluc-30UTRmt_HMGA2-L (set to the value of 100%), within the same miRNA treatment. To show which
HMGA2 30UTR isoform was more stable upon miRNA treatments, Rluc-30UTRwt_HMGA2-L values were normalized to those of
Rluc-30UTRwt_HMGA2-S (set to the value of 100%), within the same miRNA treatment. For the splicing reporter assay, the genomic
region ofHMGA2-L exon 4 along with 500bp on either side (Luc-exon-4-WT) was cloned in between the splicing acceptor and donor
sequence of a spliced Fluc ORF reporter plasmid (pcDNA3.1-Luc (Martone et al., 2016)). The mutant derivative of the SRSF1 site
within exon 4 was generated by deleting its consensus motif.
Transfection of miRNA hairpin inhibitors
CD34+ cells isolated from CB were seeded at a density of 1.6x105/well in a 12-well plate and pre-stimulated for 4 hr in StemSpan
SFEM (StemCell Technologies) supplemented with FLT3, SCF, IL-6 and TPO, as indicated. miRIDIAN miRNA hairpin inhibitorse4 Cell Stem Cell 22, 575–588.e1–e7, April 5, 2018
(Dharmacon) were transfected using DOTAP Liposomal Transfection Reagent (Sigma-Aldrich). After 24 hr, the media was replaced
with fresh media and cells were harvested at 72 hr post-transfection.
METHOD DETAILS
RNA and DNA sequencing libraries
RNAwas extracted from cells using themiRNeasy kit (QIAGEN). Transcriptional profiling of HSC and PROG populations and HPC-5F
cells transduced with CLK3/HMGA2 constructs was generated from 100 ng of total RNA for each biological replicate using the Tru-
seq RNA Library Preparation Kit v2 (Illumina). Transcriptional profiles of BM-HSCs transduced with CLK3 and HMGA2-S+30UTRwt
constructs was performed from 1-5 ng of total RNA using the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech) in combination with
the Nextera XT DNA Library Preparation Kit from 150 pg of cDNA (Illumina). ChIP-seq libraries were performed as previously
described (Cacchiarelli et al., 2015) after immunoprecipitation with antibodies for V5 (MBL Int., Lot #5) and H3K4me2 (Diagenode).
Libraries were sequenced on an Illumina HiSeq 2000 or 2500 according to protocol specifications.
miRNA profiling and analysis
For each biological replicate, 100 ng of RNA was utilized for miRNA profiling using the nCounter Human v2 miRNA Expression Assay
(NanoString Technologies). Several steps were then undertaken to normalize the Nanostring data. First, Nanostring miRNA counts
underwent QC and normalization according to manufacturer’s specifications. The normalized counts were subsequently grouped
and summed by their respective miRNA family. Then, for each sample, the expression of a given miRNA family was calculated as
a percentage of the total counts for that sample (i.e., total measured miRNA content) in the Nanostring data. A two-sided unpaired
t test was applied to compare the expression of each miRNA family across samples.
RNA-seq alignment and transcript assembly
RNA sequences were aligned using TopHat v2.0.14 (Trapnell et al., 2012) using default parameters. Sequences were aligned to the
hg19 reference genome. For the HSC/PROG samples, Gencode v17 transcript annotation was used as the transcriptome index. For
all other RNA-seq samples, Gencode v19 transcript annotations were used. For HPC-5F cells transduced withCLK3/HMGA2 and for
BM-HSCs transduced with CLK3/HMGA2-S+30UTRwt, no novel junctions were considered (using the parameter ‘‘—no-novel-
juncs’’). Visualizations and Sashimi plots of RNA-seq alignments were performed using IGV v2.3 (Robinson et al., 2011).
Downstream transcript assembly and differential expression analysis were performed using Cufflinks v2.2.1 (Trapnell et al., 2012).
For HSC/PROG samples, Cufflinks-assembled transcripts were merged with the Gencode v17 annotations using the Cuffcompare
and Cuffmerge functions to generate a ‘‘Gencode v17 + Cufflinks’’ annotation file. Novel lincRNA discovery and annotation for Cuf-
flinks-assembled transcripts was then performed according to Cabilli et al. (Cabili et al., 2011).
For the HSC/PROG transcriptome profiling, aligned sequences were quantified using the Gencode v17 + Cufflinks annotation file
using Cuffquant with default parameters. For the CLK3 and HMGA2 overexpression in BM-HSCs and HPC-5F cells, aligned se-
quences were quantified using Cuffquant with the Gencode v19 annotation file. Lastly, the Cuffnorm function was used to calculate
expression in Fragments Per Kilobase of transcript per Million mapped reads (FPKM). A mask file was used during quantification for
all datasets; this mask file was comprised of all rRNA, scRNA, snoRNA, snRNA, miRNA, ‘‘misc_RNA,’’ and tRNA sequences as an-
notated in Gencode v17 or v19. Unless otherwise noted, all Cufflinks default parameters were used.
Processed RNA-seq gene and isoform-level expression profiles for human hematopoietic cells from the cord blood lineage (n = 63
samples) were downloaded from the Blueprint Epigenome dataset (http://www.blueprint-epigenome.eu, downloaded on May
4, 2016).
We note that Gencode v17 and v19 annotate theHMGA2-S isoform (ENST00000393578) as being 316 bp in length. Newer versions
of Gencode (e.g., v27) annotate it as 911 bp, which is consistent with the observed sequencing alignments and RT-PCR. As there are
no competing exons near the HMGA2-S 30UTR, using Gencode v17 or v19 does not substantially impact our quantifications or dif-
ferential expression results.
Differential expression analyses, RT-PCR and qPCR
Differentially expressed genes and isoforms were identified using the Cuffdiff function within Cufflinks. All default parameters were
used, and a mask file as described above was applied. For the HSC/PROG data, the Gencode v17 + Cufflinks annotation was used.
For the CLK3 and HMGA2 overexpression in BM-HSCs and HPC-5F cells, the Gencode v19 annotation was used.
For the HSC and PROGdata, specific filtering criteria were applied to generate a subset of differentially expressed genes/isoforms.
For each pairwise comparison, significantly differentially expressed (FDR < 0.01) genes were identified. To define isoform-exclusive
events, we identified significantly differentially expressed (FDR < 0.01) isoforms that are non-significant (FDR > 0.01) for their corre-
sponding gene-level differential expression.
For the CLK3/HMGA2 overexpression data in BM-HSCs, significantly differentially expressed genes were defined as showing ab-
solute fold change > 2 relative to control, FPKM > 1 in either the overexpression or control sample, and FDR < 0.05.
FPKM values were plotted as the mean and standard deviation of the FPKM replicate mean values and when indicated, statistical
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Semiquantitative PCR was performed to validate isoform splicing and usage by direct amplification of the relevant exon-intron
structures. To quantify fullHMGA2mRNAs, PCRwere performed on RNA-seq libraries (performed using polyA+ capture), amplifying
the full coding sequence. To quantify HMGA2 pre-mRNA, PCR was performed on cDNA reverse transcribed with random hexamers
on polyA- RNA, amplifying a 50 portion of pre-mRNA. All PCR products were purified and run on a Bioanalyzer or Tapestation (Agilent
Technologies) to obtain digital gels from electropherograms. In each sample, HPRT1 was used as an endogenous housekeeping
control. Virtual run traces are shown at global scale visualization adjusting brightness/contrast for best representation.
Quantitative PCR (qPCR) of mRNAs and miRNAs was performed using the miScript system (QIAGEN). Outliers of technical rep-
licates were removed, and DCt or DDCt analyses were performed using HPRT1 and U6 as endogenous controls.
Definition of HSC transcriptional signatures
For HSC/PROG RNA-seq samples, significant isoforms and lincRNAs were defined as having expression of FPKM > 5 in at least one
sample, an absolute fold change > 2, and FDR < 0.05 in at least one pairwise comparison.
For HSC/PROG miRNA expression, normalized Nanostring expression data was used (see above). The mean values across sam-
ple replicates were used. miRNAs families were filtered for having an absolute fold change > 2 and a p value < 0.05 in at least one
pairwise comparison and representing > 0.1% of total measured miRNA content.
To classify these significant isoforms, lincRNAs, and miRNAs into groups, the Jensen–Shannon divergence was calculated using
the csSpecificity function implemented in CummeRbund (Trapnell et al., 2012). A specificity score > 0.25 was used to classify iso-
forms, and lincRNAs, and miRNAs as being enriched in a given sample and to define transcriptional signatures for each sample.
To generate a heatmap, the expression values were then z-score normalized, and the plotting order of isoforms, lincRNAs, or
miRNAs were based on the specificity classifications. The heatmap.2 function within the gplots package in R v3.1.1 was used to
generate the heatmap.
Gene set enrichment analysis (GSEA)
GSEA were performed as previously described using curated gene sets available in MSigdb (Subramanian et al., 2005), or gene sets
generated fromHSC and PROGgene signatures (see above). Visualization of GSEA results was performed using BubbleGum (Spine-
lli et al., 2015).
ChIP-Seq alignment and promoter analysis
Reads were aligned to the hg19 human genome using Bowtie2 (Langmead and Salzberg, 2012) with default parameters. Enrichment
at genomic 1kb tiles and promoters (defined as 1 kb up- and downstream of RefSeq transcription start sites) was computed by using
the Bedtools ‘‘coverage’’ command to count the number of reads in tile or promoter region (Quinlan and Hall, 2010). Visualizations of
ChIP-seq alignments were performed using IGV v2.3 (Robinson et al., 2011). In order to control for tiles or promoter regions with an
over- or under- enrichment of reads due to technical artifacts such as low sequence complexity, the top 15%of regions with themost
number of reads and the bottom 15%of regions with the fewest reads from the whole cell extract samples were discarded. The num-
ber of reads from sample replicates were summed to yield sample totals for each region.
Differentially-bound promoters were defined as those in which the number of both H3K4me2 and V5 reads were less than the 25th
or greater than the 75th percentile in either HMGA2-L or HMGA2-S treatments. Differentially-expressed genes from the same sam-
ples were defined as those genes that were expressed at > 5 FPKM in any sample and showed at least an absolute 2-fold change in a
comparison between two samples. RNA-seq and ChIP-seq results were then combined to study the relationship between HMGA2
occupancy on expression. The median expression and median occupancy levels were used as cutoffs to separate the data into four
quadrants.
let-7 target analysis
Data from TargetScan human version 7 was used to identify predicted conserved miRNA binding sites (www.targetscan.org). Pre-
dicted miRNA binding scores for all isoforms was kindly generated by George Bell (Whitehead Institute). The top 50% of let-7 target
isoforms were determined by having the lowest (i.e., strongest) weighted context++ scores. For target isoforms with more than one
let-7 binding site, the binding site with the strongest weighted context++ score was used. The mean expression of the let-7 target
isoforms for each sample (FL-HSC, CB-HSC, BM-HSC, FL-PROG, CB-PROG, BM-PROG, and HPC) was then calculated. The
mean expressions were then z-score normalized for plotting.
PSI analysis
Percent-spliced-in (PSI) analysis was performed using SUPPA (Alamancos et al., 2015). Splicing events (alternative 50 splice site [A5],
alternative 30 splice site [A3], alternative first exon [AF], alternative last exon [AL], mutually exclusive exon [MX], retained intron [RI],
and skipping exon [SE]) were generated from theGencode v19 annotation file or Gencode v17 +Cufflinks annotation file using default
parameters. Input RNA-seq quantifications were based on the RNA-seq quantifications as described above, except FPKM expres-
sion values were converted to transcripts per kilobase million (TPM) as recommended by the software developers. Events were
filtered for TPM > 1. PSI calculations were then performed using the ‘‘psiPerEvent’’ tool. Differential splicing analysis was performede6 Cell Stem Cell 22, 575–588.e1–e7, April 5, 2018
using the ‘‘diffSplice’’ tool. Default parameters were used, and the ‘‘empirical’’ method was used to calculate significance. A p value
threshold of 0.05 was used for declaring significance. Of note, the direction of dPSI for SE events was flipped from the software
default to reflect actual splicing changes.
Splicing factor screen
To identify candidate splicing factors for HMGA2 splicing, we applied several filters. We selected genes from the GO category ‘‘RNA
binding’’ (GO:0003723). We then filtered for candidate genes that display an absolute fold change > 2 in FL-HSCs versus CB-HSCs
and expressed at FPKM>10 in either those samples. Among the filtered candidates genes, 23 genes available as lentiviral constructs
from the Broad Institute Genome Perturbation Platform (GPP) were subsequently tested through overexpression in PC-3 cells.
Identification of SRSF1 binding motif
A search for SRSF1 binding sites was performed using the scanMotifGenomeWide function in HOMER (http://homer.ucsd.edu/
homer/motif/genomeWideMotifScan.html) usign the hg19 reference genome (Heinz et al., 2010). All software default parameters
were used. The SRSF1 binding position-weightedmatrix from (Wang et al., 2011) was used. A p value threshold of 1x10-8 was applied
and only ‘‘+’’ strand hits were kept.
RNA binding protein enrichment
The PSI data from above was used to generate exons skipped (SE events) upon CLK3 overexpression in BM-HSCs as compared to
control. A p value threshold from the PSI analysis of 0.05 was used to identify exons that are preferentially increased or decreased
upon CLK3 overexpression. Background control exons were identified using exons with p value > 0.10. The rMAPS v1.0.6 online
software (http://rmaps.cecsresearch.org) was used to perform the enrichment analysis (Park et al., 2016). All default parameters
were used in the enrichment analysis, including the binding motifs provided by the software.
QUANTIFICATION AND STATISTICAL ANALYSIS
No statistical methods were used to predetermine sample size. In general, as descriptive statistics, we reported mean ± SEM values
with the exception of RNA-seq data where we reported mean ± SD values. If not stated otherwise, t test (for two groups) or ANOVA
(more than two groups) were the standard statistical tests applied. Pairing, repeated-measurements, or other test corrections were
applied as needed. To assess statistical significance for CFU measurements, we applied analysis of deviance for generalized linear
models (Chambers andHastie, 1991). For in vivo engraftment capacity, theMann-Whitney test was applied individually by comparing
each treated sample with respect to the control sample.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq, ChIP-seq, and miRNA nanostring data reported in this paper is GEO: GSE109093.Cell Stem Cell 22, 575–588.e1–e7, April 5, 2018 e7
